A Phase 2 interventional study of Daratumumab and Bortezomib Injection in Light Chain (AL) Amyloidosis, Stage 3B, sponsored by Stichting European Myeloma Network. Completed at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Stichting European Myeloma Network · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Amyloidosis with a site in France — 17 open to participants now, 22 under way, 8 of them phase 3. Amyloidosis · France.
Among the 56 studies in Amyloidosis with a site in France, this one is the 38th largest by enrollment of the 48 interventional ones that give a count, is one of 5 that started in 2019, is one of 10 in phase 2, and was the 27th registered.
290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.
Browse Amyloidosis studies →17 of the 56 studies in Amyloidosis with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 18+
Alnylam Pharmaceuticals · Sites in France, United States, Argentina and 19 more countries
Ages 18–85
Alnylam Pharmaceuticals · Sites in France, United States, Argentina and 33 more countries
Ages 18–85
Idoven 1903 S.L. · Sites in France, United States, Germany and 2 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 25
First in 2001; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 46 across 189 interventional studies indexed under Amyloidosis.
Median enrollment 145 across the 48 interventional studies, 601 across the 8 observational. Of the 34 that completed or were terminated, 19 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 56 have an industry lead sponsor. The 10 most frequent:
Stichting European Myeloma Network is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Stichting European Myeloma Network has 1 study filed under Amyloidosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Amyloidosis with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06978660Idoven 1903 S.L.Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis | 2026-12 |
| NCT05652335Janssen Research & Development, LLCA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis | 2027-04-19 |
| NCT07721350Hospices Civils de LyonProspective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System | 2027-05 |
| NCT07549841Nantes University HospitalExploratory Study Evaluating the Relevance of [68Ga]Ga-FAPI-46 for Staging and Identifying Progressing Patients With Transthyretin Cardiac Amyloidosis | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 56 studies in Amyloidosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed stage 3B light chain (AL) amyloidosis.
The current study aims to investigate daratumumab as a monotherapy in patients with stage 3B AL amyloidosis who have not received prior therapy. Approximately 40 subjects will receive primary therapy with daratumumab. Subject participation will include a Screening Phase, a Treatment Phase, a Post-Treatment Observation Phase, and a Long-term Follow-up Phase.
A safety run-in will be conducted in 6 subjects treated with daratumumab for at least 1 cycle to establish safety of daratumumab in patients with stage 3B AL amyloidosis. Dosing of these 6 subjects will be staggered so that no subject will receive their first dose sooner than 48 hours after the previously enrolled subject. Safety evaluation will be performed by a Data Safety Monitoring Board (DSMB) after at least 1 cycle is completed for all 6 subjects. If no safety signal is observed, the enrollment of the rest of the patients will begin.
In Protocol Version 1.0, subjects receive daratumumab IV at a dose of 16 mg/kg. As of Protocol Amendment 1, all new subjects are dosed subcutaneously with daratumumab co-formulated with recombinant human hyaluronidase rHuPH20 (daratumumab SC). Subjects who already began treatment with daratumumab IV (i.e., prior to Amendment 1) switch to daratumumab SC on the next administration date according to the protocol schedule. Subjects receive daratumumab IV at a dose of 16 mg/kg and daratumumab SC at a fixed dose of 1800 mg for the first 8 weeks (Cycles 1 and 2) of treatment and then every 2 weeks for 4 cycles (Cycles 3 to 6) and then every 4 weeks until progression of disease (according to MOD-PFS), unacceptable toxicity or subsequent therapy, for a maximum of 2 years in total. All treatment cycles are 4 weeks (28 days) in length.
Subjects who will not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab, bortezomib (1.3 mg/m2 weekly for a maximum of 6 cycles) and low dose dexamethasone (total maximum weekly dose of 20mg).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
KEY INCLUSION CRITERIA
Diagnosis of amyloidosis, AL type, based on:
Histopathological diagnosis of amyloidosis based on detection by immunohistochemistry and polarizing light microscopy of green bi-refringent material in Congo Red stained tissue specimens (excluding bone marrow) or characteristic electron microscopy appearance
Considerations for specific populations where other types of amyloidosis may be encountered:
of amyloid light chain amyloidosis as defined by at least ONE of the following:
AND
Subject must have pre-treatment clinical laboratory values meeting the following criteria during the Screening Phase:
Exclusion Criteria:
Any potential subject who meets any of the following criteria will be excluded from participating in the study:
Evidence of significant cardiovascular conditions as specified below:
Diagnosed or treated for other than AL, except:
Subjects known to be:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Daratumumab monotherapy 16 mg/kg intravenous infusion (iv) or 1800 mg subcutaneous injection (sc) weekly for Cycles 1-2, every 2 weeks for Cycles 3-6 and every 4 weeks thereafter. Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive, in addition to daratumumab, bortezomib (for a maximum of 6 cycles) and low dose dexamethasone.
Drug: Daratumumab · Drug: Bortezomib Injection · Drug: Dexamethasone oral tablet
As of Protocol Amendment 1, all new subjects are dosed with daratumumab subcutaneous injection (SC) co-formulated with recombinant human hyaluronidase rHuPH20. Subjects who already began treatment with daratumumab intravenous (IV) infusion (i.e., prior to Am 1) switch to SC on the next administration date according to the protocol schedule. Subjects receive daratumumab IV at a dose of 16 mg/kg and daratumumab SC at a fixed dose of 1800 mg for the first 8 weeks (Cycles 1 and 2) of treatment and then every 2 weeks for 4 cycles (Cycles 3 to 6) and then every 4 weeks until progression of disease (according to MOD-PFS), unacceptable toxicity or subsequent therapy, for a maximum of 2 years in total. All treatment cycles are 4 weeks (28 days) in length.
Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab, bortezomib at a dose of 1.3 mg/m2 weekly for a maximum of 6 cycles as a subcutaneous injection
Also known as: velcade
Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab low dose dexamethasone at a maximum total dose of 20 mg weekly.
Overall Survival
percentage of participants
Time frame: 6 months
Overall Response Rate (ORR)
Best hematologic response rates, per International Amyloidosis Consensus Criteria: CR Normalization of free light chain ratio, negative serum and urine immunofixation; VGPR with baseline dFLC ≥ 50 mg/L, reduction in the dFLC to \<40 mg/L; PR b. baseline dFLC ≥ 50 mg/L, reduction in dFLC by ≥ 50% c. A greater than 50% reduction in M protein concentration, baseline dFLC is \<50 mg/L, M protein (≥5 g/L) d. baseline dFLC ≥ 20 and \< 50 mg/dL: dFLC \< 10 mg/dL; No response, Less than a PR;
Time frame: Overall (up to 9 months), 3 and 6 months
Major Organ Deterioration Progression-Free Survival (MOD-PFS).
Major Organ Deterioration Progression-Free Survival (MOD-PFS) is a composite endpoint of clinically observable endpoints and will be defined from the start of study treatment (Cycle 1 Day 1) to any one of the following events (whichever occurs first) • Death or Major organ deterioration
Time frame: Overall up to death or major organ deterioration
Progression Free Survival
documentation of hematologic disease progression, or organ (cardiac, renal, or liver) progression/need for transplant, or need for additional therapy (excluding the addition of bortezomib under protocol) or death due to any cause, whichever occurs first according to central laboratory results and judged by international consensus guidelines
Time frame: Overall up to 2 years
Time to Hematologic Response
to evaluate the time to hematologic response
Time frame: overall up to 2 years
Proportion of Additional Treatment
The proportion of subjects who received additional treatment with bortezomib and low dose dexamethasone (at the investigator's discretion).
Time frame: every 28 days, from start of study treatment (cycle 1 Day1) until end of treatment with a maximum of 2 years, average of 6 months
Organ Response Rate (OrRR) Heart
the organ response rate for the heart
Time frame: at 3 months, 6 months, 9 months, 12 months, 18 months, 24 months (maximum of 2 years)
EORTC QLQ-C30 Scores Will be Summarized at Each Time Point.
The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ Quality-of-Life (QoL) scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100, a high score for functional scales and for Global Health Status/QoL represent better functioning ability or Health-Related Quality-of-Life (HRQoL), whereas a high score for symptom scales and single items represents significant symptomatology.
Time frame: Score changes from baseline to 4 months
Organ Response Rate (OrRR) Kidney
the organ response rate for kidney involvement
Time frame: from registration to the date of disease progression or death with a maximum of 2 years
Organ Response Rate (OrRR) Liver
the organ response rate for liver involvement
Time frame: from registration to the date of disease progression or death with a maximum of 2 years
EORTC QLQ-C30 Scores to End of Treatment
The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ Quality-of-Life (QoL) scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100, a high score for functional scales and for Global Health Status/QoL represent better functioning ability or Health-Related Quality-of-Life (HRQoL), whereas a high score for symptom scales and single items represents significant symptomatology.
Time frame: Score changes from baseline to end of treatment (EOT)
Forty patients were included between 23 September 2019 and 12 January 2023.
| Milestone | Daratumumab |
|---|---|
| Started | 40 |
| Completed | 13 |
| Not completed | 27 |
| Withdrew: Adverse event | 3 |
| Withdrew: Death | 14 |
| Withdrew: Physician decision | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Lack of efficacy | 7 |
percentage of participants
| Percentage of participants alive at 6 mo | Daratumumab |
|---|---|
| Overall Survival | 65.0 (51.0 to 76.0) |
Best hematologic response rates, per International Amyloidosis Consensus Criteria: CR Normalization of free light chain ratio, negative serum and urine immunofixation; VGPR with baseline dFLC ≥ 50 mg/L, reduction in the dFLC to \<40 mg/L; PR b. baseline dFLC ≥ 50 mg/L, reduction in dFLC by ≥ 50% c. A greater than 50% reduction in M protein concentration, baseline dFLC is \<50 mg/L, M protein (≥5 g/L) d. baseline dFLC ≥ 20 and \< 50 mg/dL: dFLC \< 10 mg/dL; No response, Less than a PR;
| Participants | Daratumumab |
|---|---|
| Overall — VGPR | 10 |
| Overall — CR | 11 |
| Overall — PR | 9 |
| Overall — No response | 7 |
| Overall — Death before 2 efficacy assessments | 3 |
| 3 months — VGPR | 13 |
| 3 months — CR | 2 |
| 3 months — PR | 13 |
| 3 months — No response | 9 |
| 3 months — Death before 2 efficacy assessments | 3 |
| 6 months — VGPR | 14 |
| 6 months — CR | 5 |
| 6 months — PR | 11 |
| 6 months — No response | 7 |
| 6 months — Death before 2 efficacy assessments | 3 |
Major Organ Deterioration Progression-Free Survival (MOD-PFS) is a composite endpoint of clinically observable endpoints and will be defined from the start of study treatment (Cycle 1 Day 1) to any one of the following events (whichever occurs first) • Death or Major organ deterioration
| months | Daratumumab |
|---|---|
| Major Organ Deterioration Progression-Free Survival (MOD-PFS). | 9.46 (2.79 to 26.97) |
documentation of hematologic disease progression, or organ (cardiac, renal, or liver) progression/need for transplant, or need for additional therapy (excluding the addition of bortezomib under protocol) or death due to any cause, whichever occurs first according to central laboratory results and judged by international consensus guidelines
| months | Daratumumab |
|---|---|
| Progression Free Survival | 8.46 (2.79 to 18.50) |
to evaluate the time to hematologic response
| months | Daratumumab |
|---|---|
| Time to Hematologic Response | 0.23 (0.23 to 0.92) |
The proportion of subjects who received additional treatment with bortezomib and low dose dexamethasone (at the investigator's discretion).
| Participants | Daratumumab |
|---|---|
| Patients who received ≥1 bortezomib dose in addition to daratumumab | 10 |
| Patients with ≥1 low dose dexamethasone administration | 9 |
the organ response rate for the heart
| Participants | Daratumumab |
|---|---|
| 3 months — Response | 9 |
| 3 months — No response | 7 |
| 3 months — Progression | 8 |
| 3 months — Treatment discontinuation before the cutoff point | 15 |
| 3 months — Not evaluated | 1 |
| 6 months — Response | 12 |
| 6 months — No response | 4 |
| 6 months — Progression | 7 |
| 6 months — Treatment discontinuation before the cutoff point | 17 |
| 6 months — Not evaluated | 0 |
| 9 months — Response | 12 |
| 9 months — No response | 3 |
| 9 months — Progression | 4 |
| 9 months — Treatment discontinuation before the cutoff point | 20 |
| 9 months — Not evaluated | 1 |
| 12 months — Response | 15 |
| 12 months — No response | 1 |
| 12 months — Progression | 1 |
| 12 months — Treatment discontinuation before the cutoff point | 23 |
| 12 months — Not evaluated | 0 |
| 18 months — Response | 13 |
| 18 months — No response | 0 |
| 18 months — Progression | 1 |
| 18 months — Treatment discontinuation before the cutoff point | 25 |
| 18 months — Not evaluated | 1 |
| 24 months — Response | 11 |
| 24 months — No response | 2 |
| 24 months — Progression | 0 |
| 24 months — Treatment discontinuation before the cutoff point | 27 |
| 24 months — Not evaluated | 0 |
The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ Quality-of-Life (QoL) scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100, a high score for functional scales and for Global Health Status/QoL represent better functioning ability or Health-Related Quality-of-Life (HRQoL), whereas a high score for symptom scales and single items represents significant symptomatology.
| score on a scale | Daratumumab |
|---|---|
| summary score | 1.8 ± 20.1 |
| Physical functioning | -1.4 ± 25.3 |
| Role functioning | 0.7 ± 38.8 |
| Emotional functioning | 3.2 ± 15.9 |
| Cognitive functioning | 4.5 ± 11.7 |
| Social functioning | 0.8 ± 40.6 |
| Global health status/QoL | 0.4 ± 12.5 |
| Fatigue | 2.3 ± 34.6 |
| Nausea / vomiting | -5.6 ± 16.9 |
| Pain | 6.5 ± 30.9 |
| Dyspnea | -11.1 ± 37.0 |
| Insomnia | -9.1 ± 35.9 |
| Appetite loss | -7.6 ± 34.0 |
| Constipation | 12.1 ± 26.3 |
| Diarrhea | -7.6 ± 20.4 |
| Financial problems | -1.5 ± 12.5 |
the organ response rate for kidney involvement
| Participants | Daratumumab |
|---|---|
| 3 months — Response | 1 |
| 3 months — No response | 8 |
| 3 months — Progression | 2 |
| 3 months — Treatment discontinuation before the cutoff point | 8 |
| 3 months — Not evaluated | 1 |
| 6 months — Response | 3 |
| 6 months — No response | 5 |
| 6 months — Progression | 3 |
| 6 months — Treatment discontinuation before the cutoff point | 9 |
| 6 months — Not evaluated | 0 |
| 9 months — Response | 3 |
| 9 months — No response | 6 |
| 9 months — Progression | 1 |
| 9 months — Treatment discontinuation before the cutoff point | 10 |
| 9 months — Not evaluated | 0 |
| 12 months — Response | 4 |
| 12 months — No response | 4 |
| 12 months — Progression | 2 |
| 12 months — Treatment discontinuation before the cutoff point | 10 |
| 12 months — Not evaluated | 0 |
| 18 months — Response | 6 |
| 18 months — No response | 1 |
| 18 months — Progression | 1 |
| 18 months — Treatment discontinuation before the cutoff point | 11 |
| 18 months — Not evaluated | 1 |
| 24 months — Response | 3 |
| 24 months — No response | 3 |
| 24 months — Progression | 2 |
| 24 months — Treatment discontinuation before the cutoff point | 12 |
| 24 months — Not evaluated | 0 |
the organ response rate for liver involvement
| Participants | Daratumumab |
|---|---|
| 3 months — No response | 4 |
| 3 months — Treatment discontinuation before the cutoff point | 1 |
| 6 months — No response | 4 |
| 6 months — Treatment discontinuation before the cutoff point | 1 |
| 9 months — No response | 3 |
| 9 months — Treatment discontinuation before the cutoff point | 2 |
| 12 months — No response | 2 |
| 12 months — Treatment discontinuation before the cutoff point | 3 |
| 18 months — No response | 2 |
| 18 months — Treatment discontinuation before the cutoff point | 3 |
| 24 months — No response | 1 |
| 24 months — Treatment discontinuation before the cutoff point | 4 |
The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ Quality-of-Life (QoL) scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100, a high score for functional scales and for Global Health Status/QoL represent better functioning ability or Health-Related Quality-of-Life (HRQoL), whereas a high score for symptom scales and single items represents significant symptomatology.
| score on a scale | Daratumumab |
|---|---|
| summary score | 1.7 ± 20.1 |
| Physical functioning | -0.4 ± 31.2 |
| Role functioning | 7.6 ± 41.1 |
| Emotional functioning | -0.1 ± 16.9 |
| Cognitive functioning | -2.5 ± 16.0 |
| Social functioning | -1.5 ± 41.1 |
| Global health status/QoL | 2.9 ± 23.3 |
| Fatigue | -0.8 ± 36.5 |
| Nausea / vomiting | -5.1 ± 19.3 |
| Pain | 6.2 ± 28.3 |
| Dyspnea | -6.9 ± 38.3 |
| Insomnia | -8.8 ± 33.1 |
| Appetite loss | -3.9 ± 30.4 |
| Constipation | -2.0 ± 16.3 |
| Diarrhea | -4.9 ± 21.9 |
| Financial problems | -1.0 ± 15.3 |
Collected over from signing of the informed Consent Form until 30 days after the last dose of study treatment, up to 25 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Daratumumab | 20/40 (50%) | 31/40 (77.5%) | 40/40 (100%) |
| Event | Daratumumab |
|---|---|
| Cardiac failureCardiac disorders | 7/40 |
| hematologic progressionBlood and lymphatic system disorders | 5/40 |
| sudden cardiac deathCardiac disorders | 4/40 |
| Cardiac failure congestiveCardiac disorders | 3/40 |
| Acute kidney injuryRenal and urinary disorders | 3/40 |
| COVID-19Infections and infestations | 2/40 |
| SepsisInfections and infestations | 2/40 |
| Septic ShockInfections and infestations | 2/40 |
| Atrial fibrillationCardiac disorders | 1/40 |
| Atrial thrombosisCardiac disorders | 1/40 |
| Event | Daratumumab |
|---|---|
| Edema peripheralGeneral disorders | 17/40 |
| ConstipationGastrointestinal disorders | 13/40 |
| Orthostatic hypotensionVascular disorders | 11/40 |
| FatigueGeneral disorders | 9/40 |
| Cardiac failureCardiac disorders | 8/40 |
| DyspneaCardiac disorders | 7/40 |
| Eastern Cooperative Oncology Group performance status worsenedInvestigations | 7/40 |
| HypokalemiaMetabolism and nutrition disorders | 7/40 |
| AnemiaBlood and lymphatic system disorders | 6/40 |
| NauseaGastrointestinal disorders | 6/40 |
| Age, Customized(years) | Daratumumab |
|---|---|
| Age in years | 70.1 ± 10.1 |
| Race/Ethnicity, Customized(Participants) | Daratumumab |
|---|---|
| Race — White | 36 |
| Race — Not reported | 4 |
| organ involvement apart from the heart(Participants) | Daratumumab |
|---|---|
| No | 7 |
| Yes | 33 |
| Age, Customized(Participants) | Daratumumab |
|---|---|
| <75 years | 26 |
| ≥75 years | 14 |
| Sex: Female, Male(Participants) | Daratumumab |
|---|---|
| Female | 18 |
| Male | 22 |
| ECOG(Participants) | Daratumumab |
|---|---|
| 1= Symptoms, but nearly ambulatory | 16 |
| 2= Some bedtime, but to be in bed <50% of normal daytime | 21 |
| 3= Needs to be in bed >50% of normal daytime | 3 |
| NYHA classification(Participants) | Daratumumab |
|---|---|
| II | 20 |
| IIIA | 19 |
| IIIB | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2019 to primary completion in Jan 2025, 64 months.
Results were first posted in Nov 2026, 1 year 9 months after primary completion.
Of 24 phase 2 interventional studies under Amyloidosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 64. This study's 64 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daratumumab
Stichting European Myeloma Network